Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FluvalAB
- Development stage
- Phase 4
- Lead developer
- Omninvest
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FluvalAB is a seasonal trivalent, inactivated whole-virion influenza vaccine developed and manufactured by Omninvest Ltd. in Hungary. The vaccine is adjuvanted with aluminum phosphate and contains inactivated whole influenza virus particles, with a standard formulation of 15 µg of hemagglutinin (HA) per virus strain. Unlike split-virion or subunit vaccines, FluvalAB utilizes the entire inactivated virus to confer protection against influenza virus infection by stimulating the immune system's response to surface antigens, particularly hemagglutinin. First authorized in Hungary in 1995, it has been used in over 16 million vaccinations and has consistently met European Medicines Agency (EMEA) requirements for interpandemic influenza vaccines. Clinical evaluations, including Phase 4 serologic studies, have demonstrated its immunogenicity in healthy adults.
- Brand names
- FluvalABFluval AB
- Other names
- trivalent inactivated whole-virion influenza vaccineFluvalAB influenza vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on FluvalAB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FluvalAB.